In summary, our results demonstrate that the combination of berberine and evodiamine effectively reduces body weight and fat mass, improves lipid and glucose metabolism, and enhances insulin sensitivity in vivo, highlighting the potential of BBE as a therapeutic agent for obesity and related metabolic disorders. The gene discussed is INS; the disease is obesity disorder.